# US 2001/0055570 A1 · cGMP PDE 5 Inhibitors for inhalation in the treatment of sexual dysfunction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0055570 A1
- Document ID: US20010055570A1
- Status: Published application
- Kind: A1
- Application number: 09/883,572
- Filed: 2001-06-18
- Published: 2001-12-27
- Earliest claimed: 1998-12-22
- Inventors: Reto Naef
- Web page: https://patentgrep.com/patent/US20010055570A1

## CPC

- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Treatment of sexual dysfunction by inhalation of a cGMP PDE 5 inhibitor, especially 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl) quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl) quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.

## Claims

### Claim 1

A method of treating sexual dysfunction which comprises administering by inhalation an effective amount of an inhibitor of cGMP PDE 5 to a subject in need of such treatment.

### Claim 2 (depends on 1)

A method according to claim 1, in which said inhibitor is a pyrazolopyrimidinone or an aminoquinazoline derivative.

### Claim 3 (depends on 2)

A method according to claim 2, in which said inhibitor is a pyrazolopyrimidinone as disclosed in published International Patent Application No. WO94/28902, WO96116657 or WO98/49166 or published European Patent Application No EP-A-0636626, a 4-aminoquinazoline derivative as disclosed in U.S. Pat. No. 5,436,233, an arylpyrazolopyrimidinone as disclosed in published International Patent Application No. WO96/28448 or a 6-heterocyclyl-pyrazolo[3,4-d]pyrimidin-4-one as disclosed in U.S. Pat. No. 5,294,612.

### Claim 4 (depends on 3)

A method according to claim 3, in which said inhibitor is 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.

### Claim 5 (depends on 1)

A method according to claim 1, in which the inhalable form of said medicament is an atomisable composition or a finely divided particulate form.

### Claim 6 (depends on 2)

A method according to claim 2, in which the inhalable form of said medicament is an atomisable composition or a finely divided particulate form.

### Claim 7 (depends on 3)

A method according to claim 3, in which the inhalable form of said medicament is an atomisable composition or a finely divided particulate form.

### Claim 8 (depends on 5)

A method according to claim 5, in which said inhalable form is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.

### Claim 9 (depends on 6)

A method according to claim 6, in which said inhalable form is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.

### Claim 10 (depends on 7)

A method according to claim 7, in which said inhalable form is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.

### Claim 11

A method according to claim S, in which said inhalable form is a finely divided particulate form comprising said inhibitor in finely divided particulate form, optionally together with a particulate carrier.

### Claim 12 (depends on 6)

A method according to claim 6, in which said inhalable form is a finely divided particulate form comprising said inhibitor in finely divided particulate form, optionally together with a particulate carrier.

### Claim 13 (depends on 7)

A method according to claim 7, in which said inhalable form is a finely divided particulate form comprising said inhibitor in finely divided particulate form, optionally together with a particulate carrier.

### Claim 14

A medicament comprising a cGMP PDE 5 inhibitor as disclosed in WO94/28902, WO96/16657, WO98/49166, EP-A-0636626 or U.S. Pat. No. 5,436,233 in inhalable form.

### Claim 15 (depends on 14)

A medicament according to claim 14, in which the inhibitor is 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo [4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, or 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one.

### Claim 16 (depends on 14)

A medicament according to claim 14, in which the inhalable form is an atomisable composition or a finely divided particulate form.

### Claim 17 (depends on 14)

A medicament according to claim 14, in which the inhalable form is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.

### Claim 18 (depends on 15)

A medicament according to claim 15, in which the inhalable form is an atomisable composition or a finely divided particulate form.

### Claim 19 (depends on 15)

A medicament according to claim 15, in which the inhalable form is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.

### Claim 20 (depends on 15)

A medicament according to claim 15, in which the inhalable form is a finely divided particulate form comprising said inhibitor in finely divided particulate form, optionally together with a particulate carrier.
